<p>Retinitis Pigmentosa (RP) is defined as a large group of inherited vision disorders that cause progressive retina's progressive degeneration. Retinitis Pigmentosa causes the breakdown of photoreceptor cells (cells in the retina that detect light). Most forms of Retinitis Pigmentosa initially cause the breakdown of rod cells. These forms of Retinitis Pigmentosa, sometimes called rod-cone dystrophy, usually begin with night blindness.</p>
<p>About half of people with the disease have another family member with the condition. RP is passed from generation to generation can tell, who in the family has had the condition, how severely the vision could be affected, and the chances of the children being affected.</p>
<h2><strong>Retinitis Pigmentosa Epidemiological Segmentation</strong></h2>
<p>The Epidemiological Segmentation of Retinitis Pigmentosa in 7MM from 2020 to 2034 is segmented as:-</p>
<ul>
<li>Gender-Specific Diagnosed Prevalence in the 7MM</li>
<li>Type-Specific Diagnosed Prevalence in the 7MM</li>
<li>Sub-Type Specific Diagnosed Prevalence of Syndromic and Systemic Retinitis Pigmentosa in the 7MM</li>
<li>Sub-Type Specific Diagnosed Prevalence of Non-Syndromic Retinitis Pigmentosa in the 7MM</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/retinitis-pigmentosa-epidemiology-forecast"><span style="text-decoration: underline;"><strong>Retinitis Pigmentosa Epidemiology</strong></span></a></h2>
<ul>
<li>The diagnosed Retinitis Pigmentosa prevalent population in the 7MM was ~274,000 in 2023.</li>
<li>The diagnosed prevalence of Retinitis Pigmentosa in the United States was ~113,000 in 2023.</li>
<li>Nonsyndromic retinitis pigmentosa is more prevalent than syndromic retinitis pigmentosa with ~65% cases of total retinitis pigmentosa.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/retinitis-pigmentosa-market"><span style="text-decoration: underline;"><strong>Retinitis Pigmentosa Market</strong></span></a></h2>
<p>Retinitis Pigmentosa Market Size in the 7MM in 2023 was&nbsp; ~USD 500 million</p>
<h2>Retinitis Pigmentosa Market Drivers</h2>
<ul>
<li>Increasing R&amp;D Activities</li>
<li>Market share</li>
<li>Raising Awareness</li>
<li>Novel Curative Therapies</li>
</ul>
<h2>Retinitis Pigmentosa Market Barriers</h2>
<ul>
<li>Lack of awareness about the disease</li>
<li>Complex Pathophysiology</li>
<li>Lack of Clinically Relevant Biomarker</li>
<li>The high cost of therapy</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/retinitis-pigmentosa-pipeline-insight"><span style="text-decoration: underline;"><strong>Retinitis Pigmentosa Emerging Drugs</strong></span></a></h2>
<p>The emerging drugs of the Retinitis Pigmentosa market are</p>
<ul>
<li>AGTC-501</li>
<li>Botaretigene sparoparvovec)</li>
<li>4D-125&nbsp;</li>
<li>Ultevursen</li>
<li>CTx-PDE6b</li>
<li>OCU400</li>
</ul>
<p>And many others.</p>
<h2><strong>Retinitis Pigmentosa Key Players</strong></h2>
<p>The key players in the Retinitis Pigmentosa market are</p>
<ul>
<li>Beacon Therapeutics</li>
<li>MeiraGTx/Janssen Research &amp; Development&nbsp;</li>
<li>4D Molecular Therapeutics</li>
<li>ProQR Therapeutics/Laboratoires Thea&nbsp;</li>
<li>Coave Therapeutics</li>
<li>Ocugen&nbsp;</li>
</ul>
<p>And many others.</p>
<p><span style="background-color: transparent;">Subscribe to our newsletter series to get recent updates on </span><a style="background-color: transparent; color: #0047b2;" href="https://www.delveinsight.com/whitepaper-newsletter/retinitis-pigmentosa" target="_blank" rel="noopener noreferrer">Retinitis Pigmentosa Market Landscape</a></p>

Retinitis Pigmentosa Market

Retinitis Pigmentosa Market Infographic

Retinitis Pigmentosa Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.